CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma
Top Cited Papers
Open Access
- 1 March 2016
- journal article
- Published by Elsevier BV in Journal of Cellular Immunotherapy
- Vol. 2 (1), 28-35
- https://doi.org/10.1016/j.jocit.2014.11.001
Abstract
No abstract availableKeywords
Funding Information
- The National Natural Science Foundation of China (31270820, 81230061, 81402567)
- the National Basic Science and Development Programme of China (2012CB518103)
This publication has 26 references indexed in Scilit:
- CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial resultsBlood, 2012
- Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patientsTumor Biology, 2012
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaThe New England Journal of Medicine, 2011
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyLeukemia, 2011
- Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptorBlood, 2010
- The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma CellsIn vitroandIn vivoClinical Cancer Research, 2009
- Toward an Effective Targeted Chemotherapy for Multiple MyelomaClinical Cancer Research, 2009
- Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroupsBlood, 2006
- Cytotoxic activity of the maytansinoid immunoconjugate B-B4–DM1 against CD138+ multiple myeloma cellsBlood, 2004
- A plasmocyte selective monoclonal antibody (B‐B4) recognizes syndecan‐1British Journal of Haematology, 1996